The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BOPA/ISOPP 2019 | Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe, of the Christie NHS Foundation Trust, Manchester, UK, explains the updated license indication for dosing of pembrolizumab across all monotherapy indications; an extended duration between doses. He highlights the impact of this new 6 weekly dosing regimen on patients and pharmacists, and describes the implementation process at his institute. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.
